COMP <GO>
PH vs TMO // REVENUE GROWTH (YOY)
Parker-Hannifin Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: PH 9
— TMO 5
▲ REVENUE GROWTH (YOY) LEADER: TMO
LAST: $899.82 (-3.08%) • MKT CAP: $117.09B
revenue-growth
-0.40%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
revenue-growth
3.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PH VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PH | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 41.00% | -4.10 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.60% | 9.30% | +7.30 | PH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.2x | 30.4x | -4.20 | PH | /valuation <GO> |
| Free Cash Flow Yield | 2.85% | 2.40% | +0.45 | PH | /fcf-yield <GO> |
| Operating Margin | 21.90% | 17.40% | +4.50 | PH | /operating-margins <GO> |
| Net Profit Margin | 17.80% | 15.10% | +2.70 | PH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -0.40% | 3.90% | -4.30 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.74% | 0.24% | +0.50 | PH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.56 | 4.50 | +2.06 | PH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.70% | -0.20 | PH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.8 | 59.1 | -19.40 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.94 | -0.06 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.9x | 36.3x | -5.40 | PH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $117.09B | $262.22B | -$145.13B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PH REV | TMO REV | PH GROSS % | TMO GROSS % | PH FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $19.85B | $44.56B | 36.9% | 44.0% | $3.34B | $6.29B |
| FY 2024 | $19.93B | $42.88B | 35.8% | 44.0% | $2.98B | $7.27B |
| FY 2023 | $19.07B | $42.86B | 44.0% | 44.0% | $2.12B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PH // BETA 0.88
TMO // BETA 0.94